From GlobeNewswire: 2025-05-06 07:10:00

Neuronetics, Inc. reported first quarter 2025 revenue of $32.0 million, an 84% increase from the same period in 2024. U.S. clinic revenue was $18.7 million, U.S. treatment session revenue was $9.6 million, and U.S. NeuroStar Advanced Therapy System revenue was $2.8 million. The company completed a secondary offering, raising approximately $18.9 million in net proceeds. Neuronetics expects to achieve positive cash flow in the third quarter of 2025 and has treated over 202,000 global patients with 7.4 million treatment sessions.

Neuronetics is seeing significant operational progress with the integration of Greenbrook and has expanded insurance coverage for adolescent TMS treatment. Evernorth Health Services (Cigna) now covers adolescents 15+ for TMS therapy, joining other major insurers. The company also completed a public offering of common stock, raising approximately $18.9 million in net proceeds. Neuronetics expects total worldwide revenue for the second quarter of 2025 to be between $36.0 million and $38.0 million and between $149.0 million and $155.0 million for the full year.



Read more at GlobeNewswire: Neuronetics Reports First Quarter 2025 Financial and